Clinical Trial Update: Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain [Phase 3]

View source ↗

Summary

The Phase 3 long-term safety study of BEMA Buprenorphine in chronic low back pain has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Back Pain

Drugs mentioned

• BEMA Buprenorphine (buprenorphine)

Snippet

Sponsor: BioDelivery Sciences International | Conditions: Pain, Low Back Pain | Phase 3 | Status: WITHDRAWN